Where Were the Women? Gender Parity in Clinical Trials.

Abstract

Where Were the Women? On October 3, the FDA approved coformulated tenofovir alafenamide and emtricitabine (F/TAF) for HIV prevention in at-risk “adults and adolescents…excluding those who have rece...